Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Generic Drugs: Global collaboration opportunities
Management Report
Published: December 2011
Pages: 410
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Prescription Medicines
Key facts, statistics and insights on 160 medium-sized generic manufacturers based in 35 countries!
Collaboration is the key to growth
In the current economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems.
At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of branded medicines have made moves to increase generic prescribing.
But pressure on health spending is seeing downward pressure on generic prices. With lower margins this is creating pain for generics companies.
SME Generic companies offer focused opportunities
With established markets compromised, where can the industry go? Expansion in the sector has been seen through more partnering, either through outright acquisition to increase market share or through product and marketing licensing. Being bigger and having improved market access is seen as a way of distributing cost and strengthening revenues. While major players such as Teva and Sandoz play an international role, there are a number of established and progressive generic manufacturers worthy of consideration.
Find and assess potential partners and acquisition targets with this report
This new report from Espicom is a key resource for the wide assessment of 160 medium-sized generic companies operating in 35 markets worldwide. The report provides an essential and comprehensive evaluation of each company:
Location, establishment and full contact details
Financial information, where available
Products and/or therapy areas
Recent strategic alliances
Africa
EIPICo Egypt
Hikma Pharmaceuticals Jordan
Regal Pharmaceuticals Kenya
Oman Pharmaceutical Products Oman
Adcock Ingram South Africa
Cipla Medpro South Africa
Litha Healthcare South Africa
Pharma Dynamics South Africa
Sonke Pharmaceuticals South Africa
Asia
Beximco Pharmaceuticals Bangladesh
Aoxing Pharmaceutical China
Laiyang Jiangbo Pharmaceuticals China
Rxmidas Pharmaceuticals China
Zhejiang Huahai Pharmaceuticals China
Alembic Pharmaceuticals India
Alkem Laboratories India
Bafna Pharmaceuticals India
Bharat Serums and Vaccines India
Biocon India
Claris Lifesciences India
Emcure India
Gland Pharma India
Glenmark Pharmaceuticals India
Granules India India
Hetero Drugs India
Indoco Remedies India
Intas Pharmaceuticals India
JB Chemicals & Pharmaceuticals India
Jubilant Life Sciences India
Macleods Pharmaceuticals India
Marksans Pharma India
Micro Labs India
Natco Pharma India
Orchid Chemicals & Pharmaceuticals India
RPG Life Sciences India
Shasun Pharmaceuticals India
Strides Arcolab India
Torrent Pharmaceuticals India
Unichem Laboratories India
Venus Remedies India
Nichi-Iko Pharmaceuticals Japan
Nippon Chemiphar Japan
Towa Pharmaceutical Japan
CCM Pharmaceuticals Malaysia
Inno Biologics Malaysia
Pharmaniaga Berhad Malaysia
ScinoPharm Taiwan Taiwan
Government Pharmaceutical Organisation Thailand
Abdi Ibrahim Turkey
EastPharma Turkey
Mustafa Nevzat Pharmaceuticals Turkey
Nanogen Biopharmaceuticals Vietnam
Australasia
Alchemia Australia
Ascent Pharmahealth Australia
Europe
BioAlliance Pharma France
Alfred E Tiefenbacher Germany
Genepharm Greece
Pharmathen Greece
Consilient Health Ireland
Reliance GeneMedix Ireland
ACS Dobfar Italy
Grindeks Latvia
Sanitas Lithuania
Genmed Holdings Netherlands
Synthon Netherlands
Navamedic Norway
Polpharma Poland
Hovione FarmaCiencia Portugal
R-Pharm Russia
Laboratorios Cinfa Spain
Bluefish Pharmaceuticals Sweden
Acino Switzerland
Legacy Pharmaceuticals International Switzerland
Goldshield Group UK
Kent Pharmaceuticals UK
Syntropharma UK
North America
AA Pharma Canada
BioVectra Canada
Intellipharmaceutics International Canada
Acella Pharmaceuticals USA
Aceto USA
Akorn USA
Altaire Pharmaceuticals USA
Alvogen USA
Amerigen Pharmaceuticals USA
Amneal Pharmaceuticals USA
Amphastar Pharmaceuticals USA
Anchen Pharmaceutical USA
Antares Pharma USA
Apicore USA
APP Pharmaceuticals USA
Austarpharma USA
Avanthi USA
Banner Pharmacaps USA
Bedford Laboratories USA
Biokey USA
Boca Pharmacal USA
Breckenridge Pharmaceutical USA
Cambrex USA
Carlsbad Technology USA
Cephazone Pharma USA
Cobrek Pharmaceuticals USA
CorePharma USA
Cypress Pharmaceutical USA
Elite Pharmaceuticals USA
Epic Pharma USA
Exela Pharma Sciences USA
Ferndale Pharma Group USA
Fougera USA
G&W Laboratories USA
GeneraMedix Pharmaceuticals USA
Greenstone USA
Handa Pharmaceuticals USA
Hanford Pharmaceuticals USA
Harris Pharmaceutical USA
Heritage Pharmaceuticals USA
Hi-Tech Pharmacal USA
IGI Laboratories USA
Indicus Pharma USA
InvaGen Pharmaceuticals USA
Kadmon Pharmaceuticals USA
KUDCo USA
KVK-Tech USA
Lehigh Valley Technologies USA
Luitpold Pharmaceuticals USA
Lyne Laboratories USA
Mallinckrodt USA
Mikah Pharma USA
Mikart USA
Nexgen Pharma USA
Nexus Pharmaceuticals USA
Nostrum Pharmaceuticals USA
Novel Laboratories USA
Orit Laboratories USA
Osmotica Pharmaceutical USA
Pharmaceutical Associates USA
PharmaForce USA
Prasco Laboratories USA
Precision Dose USA
Roxane Laboratories USA
Sigmapharm Laboratories USA
Silarx Pharmaceuticals USA
SOHM USA
Spear Pharmaceuticals USA
Stason Pharmaceuticals USA
Synerx Pharma USA
ThePharmaNetwork USA
Tolmar USA
Tris Pharma USA
Upsher-Smith Laboratories USA
URL Pharma USA
Vanguard Pharmaceutical USA
VersaPharm USA
VistaPharm USA
Gen Pharmaceuticals USA
South America
Laboratorios Phoenix Argentina
Hypermarcas Brazil
LAFEPE Brazil
Moksha8 Brazil
FREE! Single-user web access to this report is now included for all buyers at no additional cost.
About the Author: Generic Drugs: Global Collaboration Opportunities has been researched and written by Espicom editor Ian Platts. In addition to this report, Ian edits the leading newsletter World Generic Markets and has monitored the generics market for over 10 years. Other reports in the series;
Multi-therapy Drugs: Opportunities for Generics & Biosimilars
(October 2011)
Highly-detailed analysis, outlook and forecasts of 24 leading drugs which are indicated for a range of critical conditions.
Hospital Injectable Drugs: Future Prospects for Generics & Biosimilars
(July 2011)
The latest edition of Espicom’s best-selling injectables report focuses on hospital drugs in therapy areas such as cancer, thrombosis, rheumatoid arthritis and serious infection. The report examines the status, value and generic/biosimilar opportunity for over 30 high-growth injectable drugs.
World Generic Market Report 2011
(February 2011)
Primary research with companies, statistics offices, health ministries and trade associations worldwide providing standard, comparative data and discussion on key issues.
Global Biosimilars: Identifying 2nd generation opportunities
(January 2011)
A critical 206-page strategic management report which provides an analysis of the regulatory challenges and market opportunities for the biosimilar sector and assesses how it may practically develop.
Use this report to…
Identify commercial partners to secure new markets, technologies and revenues
Assess merger and acquisition targets
Understand the developing generic industry in key markets worldwide
Profile the competitive environment in the increasingly important medium-sized company sector
Seek out companies manufacturing/marketing similar product lines
Assess the investment potential of these developing companies
Delivering the key content you need...
Background
A summary of the company’s foundation and main business interests
Product range
Details of ANDAs approved or products/therapy areas represented
Financial
Financial performance or funding data
Strategic alliances
Details of significant marketing and supply agreements
Contact information
Postal, telephone, fax and website details